Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance

[1]  Yuanfang Ma,et al.  Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy , 2015, Cancer science.

[2]  W. Xu,et al.  HMGB1 translocation is involved in the transformation of autophagy complexes and promotes chemoresistance in leukaemia. , 2015, International journal of oncology.

[3]  D. Wilkinson,et al.  LC3 is a novel substrate for the mammalian Hippo kinases, STK3/STK4 , 2015, Autophagy.

[4]  Cheng Wang,et al.  PI3K/Akt signaling in osteosarcoma. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[5]  Stefano Monti,et al.  A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.

[6]  Zengqiang Yuan,et al.  Mitochondrial calcium uniporter protein MCU is involved in oxidative stress-induced cell death , 2015, Protein & Cell.

[7]  J. Ajani,et al.  The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer , 2015, Clinical Cancer Research.

[8]  Jilong Yang.  Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma , 2014, Chinese journal of cancer.

[9]  H. Fan,et al.  YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells , 2014, PloS one.

[10]  Xiaohui Wang,et al.  Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells , 2014, World Journal of Surgical Oncology.

[11]  B. Mao,et al.  SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma , 2014, Oncogene.

[12]  Jing Tian,et al.  Mst1 and Mst2 kinases: regulations and diseases , 2013, Cell & Bioscience.

[13]  P. Pandolfi,et al.  ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence , 2013, Cell Death and Differentiation.

[14]  Jieun Park,et al.  Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. , 2013, International journal of oncology.

[15]  R. O’Keefe,et al.  Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. , 2013, Biochemical and biophysical research communications.

[16]  Kang Han,et al.  miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. , 2012, Oncology reports.

[17]  F. Camargo,et al.  The Hippo signaling pathway and stem cell biology. , 2012, Trends in cell biology.

[18]  Jun-bing Wu,et al.  The c-Abl-MST1 Signaling Pathway Mediates Oxidative Stress-Induced Neuronal Cell Death , 2011, The Journal of Neuroscience.

[19]  S. Hilsenbeck,et al.  Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.

[20]  Li Li,et al.  The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.

[21]  M. Sudol,et al.  Mst2 and Lats Kinases Regulate Apoptotic Function of Yes Kinase-associated Protein (YAP)* , 2008, Journal of Biological Chemistry.

[22]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[23]  G. Yan,et al.  Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. , 2008, Cancer research.

[24]  K. Irvine,et al.  In vivo regulation of Yorkie phosphorylation and localization , 2008, Development.

[25]  Kevin J. Cheung,et al.  Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.

[26]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[27]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[28]  Ryan S. Udan,et al.  Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway , 2003, Nature Cell Biology.

[29]  G. Castellani,et al.  Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. , 2003, European journal of cell biology.

[30]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. DePamphilis,et al.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. , 2001, Genes & development.

[32]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[33]  Y. Hata,et al.  The mammalian Hippo pathway: regulation and function of YAP1 and TAZ , 2014, Cellular and Molecular Life Sciences.

[34]  J. Freeman,et al.  Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. , 2009, International journal of oncology.

[35]  J. Downward,et al.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. , 2003, Molecular cell.